CD274 and neoplasm: The FDA even adjusted immunotherapy guidelines by recommending the use of Pembrolizumab in tumour mutational burden-high (TMB-H) solid tumours in patients that have progressed and have no other treatment options even if PD-L1 levels in the primary tumour are <1% [26].